Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Vaximm AG announced that VXM01, an investigational oral anti-VEGFR vaccine, was found safe and showed early signs of efficacy in combination with avelumab…
OSR Holdings (OSRH) entered a $815 million global license agreement for VXM01 with BCM Europe, which already owns approximately 29.7% of OSRH and pledged its…
Form 8-K (filed ~May 2026): OSR Holdings entered an Asset Purchase Agreement with Vaximm AG (indirect Swiss subsidiary) dated May 27, 2026 to acquire, free and…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
OSR Holdings (Nasdaq: OSRH) executed a definitive global exclusive license agreement (dated April 29, 2026) granting BCM Europe AG (BCME) — OSRH's largest shareholder at ~29.7% — worldwide rights to develop, manufacture, commercialize and sublicense VXM01, an oral live-attenuated Salmonella-vectored DNA immunotherapy targeting VEGFR-2 (Phase 2b-ready in recurrent glioblastoma). The structure provides OSRH up to $815M in clinical/regulatory/commercial milestone payments plus 100% downstream royalties after BCME recovers its investment and a preferred return, with BCME pledging its ~29.7% OSRH stake as collateral; an independent fairness opinion (Avance Life Sciences) supported the related-party deal. On May 27, 2026 OSRH signed a definitive Asset Purchase Agreement to acquire the full VXM01 IP portfolio from its Swiss subsidiary Vaximm AG for $30M, with the payment deferred until the first BCME milestone event (completion of a Phase 2 study in glioblastoma or pancreatic ductal adenocarcinoma); the license remains intact and the CEO reaffirmed it as a major oncology milestone in a May 12, 2026 shareholder statement.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BCM Europe AG / OSR Holdings, Inc. (this deal) | 2026 | $815M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals